CONCLUSION
In this retrospective cohort, AZM-Corticosteroids and therapeutic
anticoagulation, when indicated, represented a favorable combination for
patients hospitalized with COVID-19, reducing mortality, length of
hospitalization and the risk for MV. HCQ did not yield benefits to
combination therapy and we do not support its use for inpatients. HFNC
oxygen therapy was able to reduce the risk of MV support. Individuals
older than >65 years, with presence of up one comorbidity,
pulmonary involvement more than or equal to 50%, saturation
<93%, lymphopenia, D-dimers and CRP elevated on arrival, and
oxygen requirement through BiPAP or HFNC, ICU admission and MV during
hospitalization represented the set of clinical predictors for worse
prognosis.